X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The acquisition of Calypso gives Novartis full rights to CALY-002, a pipeline-in-a-drug with potential in dermatology, gastro-intestinal and rheumatology indications. CALY-002 is a potential best-in-class therapeutic antibody that binds to and neutralizes Interleukin-15.
Lead Product(s): CALY-002
Therapeutic Area: Gastroenterology Product Name: CALY-002
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $425.0 million Upfront Cash: $250.0 million
Deal Type: Acquisition January 08, 2024
Details:
Calypso Biotech has elected Celiac Disease and Eosinophilic Esophagitis to evaluate the biological and clinical efficacy of CALY-002. The study is a multi-site, randomized, placebo controlled single and multiple dose escalation study of an anti-IL-15 mAb (CALY-002).
Lead Product(s): CALY-002
Therapeutic Area: Gastroenterology Product Name: CALY-002
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
